Table 1.

Clinical characteristics of cancer patients receiving systemic therapy with prior SARS-CoV-2 infection.

Patient No.	Sex	Age	PS	Cancer diagnosis	Staging	Chronic diseases	Systemic therapy	Time of nucleic acid testing
1	Female	59	1	NPC	rT0N1M0	None	2 cycles of GP and 2 cycles of GP +PD-1 inhibitor	April 21; May 15; June 3; June 6; June 30; July 20
2	Male	41	1	NPC	T3N2M0	None	2 cycles of GP + PD-1 inhibitor; radiotherapy + 2 cycles of DDP + PD-1 inhibitor	March 25; April 17; May 29
3	Female	48	1	NPC	T3N1M0	None	Radiotherapy + 2 cycles of PD-1 inhibitor; 1 cycle of TP	April 26, May 8; June 10; June 15
4	Male	72	1	NSCLC	T3N1M0	Hypertension; Cardiovascular disease; COPD	2 cycles of abraxane and 2 cycles of abraxane + nedaplatin + PD-1 inhibitor	March 23; April 1; April 3; May 5; June 3; June 29
5	Male	64	1	NSCLC	T2N2M0	Cardiovascular disease	2 cycles of PD-1 inhibitor	April 18; May 12; May 26; June 9; July 17
6	Male	71	1	Soft tissue sarcoma	T3N0M0 G3	None	2 cycles of gemcitabine + anlotinib + PD-1 inhibitor	May 20; June 3; June 4; June 29
7	Female	51	1	Rectal cancer	rT0N0M1	None	4 cycles of XELOX + PD-1 inhibitor	April 16; May 5; May 29; July 1
8	Male	57	1	Esophagus cancer	T4aN2M0	Hypertension; Diabetes	3 cycles of capecitabine + nedaplatin + PD-1 inhibitor	March 20; June 1; July 2

Abbreviations: NPC, nasopharyngeal cancer; NSCLC, non-small cell lung cancer; COPD, chronic obstructive pulmonary disease; GP, gemcitabine and cisplatin; PD-1, programmed cell death protein 1; XELOX, oxaliplatin + capecitabine.